Alnylam Pharmaceuticals | ALNY - Loan Capital

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.04B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Moderna USD 26M 6M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Takeda JPY 4.27T 81.29B Dec/2025
Tectonic Therapeutic USD 100K 86K Sep/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xencor USD 87.78M 6.96M Sep/2025